CVS Health, CVS Pharmacy and CVS subsidiary Wellpartner were slapped with an antitrust class action Monday in Pennsylvania Eastern District Court in connection with the federal 340B drug-pricing program. The suit asserts that CVS is forcing Brandywine Hospital and similarly situated ‘safety-net’ healthcare providers to purchase services at inflated prices from Wellpartner in exchange for processing 340B-eligible prescriptions for low-income patients. The complaint was brought by Fine, Kaplan and Black; Lockridge Grindal Nauen; and Rupp Pfalzgraf LLC. Counsel have not yet appeared for the defendants. The case is 2:23-cv-01458, Brandywine Hospital, LLC v. CVS Health Corporation et al.

This suit was surfaced by Law.com Radar, a source for high-speed legal news and litigation updates personalized to your practice. Law.com Radar publishes daily updates on just-filed federal cases like this one. Click here to get started and be first to know about new suits in your region, practice area or client sector. Read the complaint here:

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]